Cigarette smoking is associated with adverse pathological response and increased disease recurrence amongst patients with muscle‐invasive bladder cancer treated with cisplatin‐based neoadjuvant chemotherapy and radical cystectomy: a single‐centre experience

To investigate the association between smoking status and pathological response to cisplatin‐based neoadjuvant chemotherapy (NAC) and survival outcomes in patients with muscle‐invasive bladder cancer (MIBC) treated with radical cystectomy (RC).

[1]  Andrew C. James,et al.  Optimization of Patient Selection for Neoadjuvant Chemotherapy in Muscle‐invasive Urothelial Carcinoma of the Bladder , 2018, Clinical genitourinary cancer.

[2]  M. Menon,et al.  Neoadjuvant chemotherapy prior to radical cystectomy for muscle‐invasive bladder cancer with variant histology , 2017, Cancer.

[3]  P. Gontero*,et al.  Prevention of bladder cancer incidence and recurrence: tobacco use , 2017, Current opinion in urology.

[4]  M. Terris,et al.  Tobacco-Specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder Cancer , 2017, Cancer Prevention Research.

[5]  Fei Li,et al.  Association of smoking status with prognosis in bladder cancer: A meta-analysis , 2016, Oncotarget.

[6]  M. Zeegers,et al.  Significant Role of Lifetime Cigarette Smoking in Worsening Bladder Cancer and Upper Tract Urothelial Carcinoma Prognosis: A Meta-Analysis. , 2016, The Journal of urology.

[7]  S. Faraj,et al.  Gemcitabine and cisplatin neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma: Predicting response and assessing outcomes. , 2015, Urologic oncology.

[8]  B. Bochner,et al.  The impact of smoking on pathologic response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer , 2014, World Journal of Urology.

[9]  M. Babjuk,et al.  Impact of smoking and smoking cessation on outcomes in bladder cancer patients treated with radical cystectomy. , 2013, European urology.

[10]  M. Babjuk,et al.  Impact of smoking and smoking cessation on oncologic outcomes in primary non-muscle-invasive bladder cancer. , 2013, European urology.

[11]  L. Kiemeney,et al.  Epidemiology and risk factors of urothelial bladder cancer. , 2013, European urology.

[12]  Choung-Soo Kim,et al.  Smoking and survival after radical cystectomy for bladder cancer. , 2012, Urology.

[13]  A. Chatterjee,et al.  Adenylate Kinase 3 Sensitizes Cells to Cigarette Smoke Condensate Vapor Induced Cisplatin Resistance , 2011, PloS one.

[14]  Y. Ho,et al.  Long-term nicotine exposure-induced chemoresistance is mediated by activation of Stat3 and downregulation of ERK1/2 via nAChR and beta-adrenoceptors in human bladder cancer cells. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[15]  H. Grossman,et al.  Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy , 2009, Cancer.

[16]  Jie Xu,et al.  Nicotine inhibits apoptosis induced by cisplatin in human oral cancer cells. , 2007, International journal of oral and maxillofacial surgery.

[17]  C. Vale.  Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration , 2005 .

[18]  M. Parmar,et al.  Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. , 2005, European urology.

[19]  Nicholas J Vogelzang,et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.

[20]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[21]  C. Balch,et al.  AJCC Cancer Staging Manual. 6th ed , 2002 .

[22]  J. Cooper.  Ajcc Cancer Staging Manual , 1997 .

[23]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.